United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $524.99, for a total value of $4,987,405.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,268,919.87. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $521.22 on Tuesday. The stock has a market capitalization of $22.85 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 1.89 and a beta of 0.84. The firm’s 50 day simple moving average is $491.17 and its 200-day simple moving average is $469.91. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $548.12.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $6.19 EPS. Analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on UTHR. HC Wainwright increased their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. TD Cowen lifted their price target on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada increased their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $549.91.

Institutional Trading of United Therapeutics

Institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. lifted its stake in United Therapeutics by 10.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock valued at $645,000 after buying an additional 127 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in United Therapeutics by 13.5% in the 4th quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock worth $9,379,000 after buying an additional 2,289 shares during the last quarter. Rehmann Capital Advisory Group increased its stake in United Therapeutics by 9.8% during the 4th quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after buying an additional 324 shares in the last quarter. Tobam raised its holdings in shares of United Therapeutics by 28.9% during the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock valued at $4,803,000 after acquiring an additional 2,211 shares during the last quarter. Finally, Wick Capital Partners LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at approximately $297,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.